HilleVax Director Receives 17k Share RSU Grant in Form 4 Filing
Rhea-AI Filing Summary
HilleVax, Inc. (HLVX) filed a Form 4 disclosing that non-employee director Shelley Chu received 17,199 shares of common stock in the form of Restricted Stock Units (RSUs) on 23 June 2025. The RSUs were awarded under the company’s 2022 Incentive Award Plan as part of the Non-Employee Director Compensation Program. The filing shows the transaction was coded “A” (acquisition) at a price of $0.00, confirming it was a grant rather than an open-market purchase.
The RSUs will vest 100 % on the earlier of (i) the first anniversary of the grant date or (ii) a Change in Control, provided Dr. Chu remains on the board until the applicable vesting date. Following the grant, Dr. Chu’s total beneficial ownership stands at 17,199 shares, held directly. No derivative securities were reported, and there were no dispositions.
The filing is routine director equity compensation, adding a small amount of potential dilution but primarily aligning the director’s interests with shareholders. No cash consideration, purchase of shares, or sales were reported, and the filing contains no financial performance metrics or strategic commentary.
Positive
- None.
Negative
- None.
Insights
TL;DR – Routine RSU grant to director; neutral impact on valuation and sentiment.
The Form 4 indicates an equity grant of 17,199 RSUs to Director Shelley Chu at no cost. Size is immaterial relative to HLVX’s ~39 million shares outstanding, implying negligible dilution. No insider buying or selling signals were provided, and vesting terms are standard. As such, the filing neither strengthens nor weakens the investment thesis; it simply documents ongoing board compensation practices.